221 related articles for article (PubMed ID: 1333066)
21. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
[TBL] [Abstract][Full Text] [Related]
22. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
25. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
Kobayashi H; Hayata T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
[TBL] [Abstract][Full Text] [Related]
26. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Levin L; Simon R; Hryniuk W
J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide.
West RJ; Zweig SF
Eur J Gynaecol Oncol; 1997; 18(5):343-8. PubMed ID: 9378150
[TBL] [Abstract][Full Text] [Related]
28. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
[TBL] [Abstract][Full Text] [Related]
29. [Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors].
Takada M; Usui N; Yoshida K; Hirayama H; Suzuki M; Takeuchi H; Wada H; Iwasa T; Yamamoto T; Nagasawa I
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):333-8. PubMed ID: 2358717
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
Ehrlich CE; Einhorn L; Williams SD; Morgan J
Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
[No Abstract] [Full Text] [Related]
31. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
Krommer CF; Szalai JP
Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
[TBL] [Abstract][Full Text] [Related]
33. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
Omura GA; Brady MF
Obstet Gynecol; 1993 Apr; 81(4):641-2. PubMed ID: 8459984
[No Abstract] [Full Text] [Related]
35. Feasibility of intraperitoneal chemotherapy in advanced epithelial ovarian cancer.
Maheshwari A; Gupta S; Prabhash K; Tongaonkar HB
Indian J Cancer; 2010; 47(2):225-6. PubMed ID: 20448394
[No Abstract] [Full Text] [Related]
36. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
Williams CJ; Stewart L; Parmar M; Guthrie D
Semin Oncol; 1992 Feb; 19(1 Suppl 2):120-8. PubMed ID: 1411623
[TBL] [Abstract][Full Text] [Related]
39. Treatment of stages II, III and IV primary surface epithelial ovarian cancers by maximum bulk tumour reduction and combined chemotherapy with cyclophosphamide, doxorubicin and cisplatin.
Khanna S; Kirwan P; Naftalin NJ; Aukett RJ
Clin Radiol; 1986 Mar; 37(2):187-91. PubMed ID: 3698507
[TBL] [Abstract][Full Text] [Related]
40. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
Bertelsen K; Jakobsen A; Andersen JE; Ahrons S; Pedersen PH; Kiaer H; Arffmann E; Bichel P; Boestofte E; Strøyer I
Gynecol Oncol; 1987 Oct; 28(2):161-9. PubMed ID: 3311924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
